Eli Lilly is still one of the strongest growth stories in large-cap pharma, powered by tirzepatide and an expanding cardiometabolic pipeline. The stock remains constructive, but valuation now demands continued execution rather than multiple expansion.
Eli Lilly(LLY) remains one of the strongest growth stories in large-cap pharma, but it is no longer a simple growth-at-any-price trade. The core investment case rests on three hard facts. First, revenue has accelerated from $34.12B in 2023 to $45.04B in 2024 and $65.18B in 2025, then to $19.799B in Q1 2026 alone, up 56% YoY. Second, the tirzepatide franchise continues to scale globally, with Mounjaro revenue at $8.7B in Q1 2026 and Zepbound U.S. revenue at $4.1B, while management raised 2026 revenue guidance to $82B-$85B and non-GAAP EPS guidance to $35.50-$37.00. Third, Lilly is extending the same cardiometabolic moat with new assets, including FDA-approved orforglipron under the trade name Koundeo and late-stage retatrutide.
That combination gives Lilly unusual depth: a dominant current franchise, a next-wave oral GLP-1, and a broader pipeline across oncology, immunology, and neuroscience. The catch is valuation. With a trailing P/E of 43.1, forward P/E of 32.8, EV/revenue of 15.24, and a market cap above $1.08T, the stock already prices in a lot of success. For a balanced, moderate-risk investor, the setup still supports a constructive stance, but the expected return now depends more on execution and earnings growth than on further multiple expansion. The stock looks like a premium compounder, not a bargain-bin miracle.
Eli Lilly(LLY) is a global human pharmaceutical company headquartered in Indianapolis, founded in 1876, with about 50,000 employees. It discovers, develops, manufactures, and markets medicines across the U.S., Europe, China, Japan, and other international markets. The company operates as a single pharmaceutical business, though its portfolio spans cardiometabolic health, oncology, immunology, and neuroscience.
The revenue base has changed dramatically in a short period. FY 2025 revenue reached $65.179B, up 45% YoY, versus $45.043B in 2024 and $34.124B in 2023. Product revenue represented $60.958B, or 93.5% of total 2025 revenue, while collaboration and other revenue contributed $4.221B. Geographically, the U.S. remained the center of gravity at $43.481B in 2025, followed by Europe at $11.558B, Japan at $2.132B, China at $1.951B, and rest of world at $6.057B.
Leadership is stable and experienced. David A. Ricks serves as Chair and CEO, Lucas Montarce as CFO, and Daniel Skovronsky as Chief Scientific & Product Officer and President of Lilly Research Laboratories. That matters because Lilly is in the middle of a scale-up phase where commercial execution, manufacturing expansion, and pipeline prioritization all need to work at once. In pharma, that is like changing the engine while the plane is climbing.
Lilly reports as a single business, but the economics are best understood through product mix and therapeutic areas. The dominant engine is cardiometabolic health, led by Mounjaro and Zepbound. In Q1 2026, Mounjaro and Zepbound generated $12.8B of combined global revenue and contributed $6.7B of growth versus Q1 2025. That is the main reason total company revenue grew 56% YoY in the quarter.
Oncology remains an important second pillar. Verzenio produced $1.6B in Q4 2025 sales, up 3% YoY, while Jaypirca delivered $148M, up 30% YoY. Management also said Jaypirca worldwide sales grew 79% in Q1 2026 versus Q1 2025, helped by momentum in chronic lymphocytic leukemia. Inluriyo, though still early, generated $14M in Q4 2025 and achieved more than 35% share of new patient starts in metastatic breast cancer during its first full U.S. launch quarter, according to management commentary.
Immunology is smaller today but moving in the right direction. Ebglyss posted $134M in Q4 2025 sales, and Omvoh delivered $88M. Management said U.S. new patient starts for Ebglyss increased 90% in Q1 2026 versus Q1 2025, with steady share gains in specialty dermatology. That is not yet large enough to drive the stock, but it adds diversification and gives Lilly more than one growth lever.
Neuroscience is the most speculative commercial bucket, though it has visible momentum. Kisunla generated $109M in Q4 2025 sales, up 54% versus Q3 2025, and management said it remains the U.S. leader in amyloid-targeting therapies. If that leadership holds as diagnostic capacity expands, neuroscience can become more than a science project and start acting like a real business line.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship franchise is tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. This is the center of Lilly’s current earnings power. In Q1 2026, Mounjaro revenue reached $8.7B, up 125% YoY, while Zepbound U.S. revenue reached $4.1B, up 79% YoY. Combined cardiometabolic revenue from Mounjaro and Zepbound was $12.8B in the quarter.
Market share data shows this is not just a hot launch but a scaling franchise. In Q4 2025, Lilly said Mounjaro held 48% total prescription share and 55% new-to-brand prescription share in the U.S. type 2 diabetes incretin analog market. Zepbound held 64% total prescription share and 69% new-to-brand share in the U.S. branded anti-obesity market. In Q1 2026, management added that Mounjaro gained another 3 percentage points of market share in U.S. diabetes incretins versus the end of 2025.
The next flagship candidate is orforglipron, now approved by the U.S. FDA under the trade name Koundeo. CEO David Ricks described it as the first new incretin medicine launched with obesity as its first indication and highlighted a key commercial advantage: it is an oral GLP-1 pill that can be taken any time of day without food or water restrictions.
That matters because oral delivery expands the addressable patient pool beyond people willing to use injectables. Lilly also said regulatory reviews are ongoing in more than 40 countries and that a U.S. submission for type 2 diabetes was planned for late Q2 2026. In ACHIEVE I, management said Koundeo showed a 16% lower risk of MACE-4 events, a 23% lower risk on a secondary cardiovascular endpoint, and a 57% survival advantage in a preplanned analysis not controlled for multiplicity versus insulin glargine. Even with the usual caution around cross-trial comparisons, those are strong data points for franchise extension.
Lilly’s moat starts with clinical relevance and extends into franchise design. Tirzepatide is already a category-defining asset, but Lilly is building layers on top of it. The 2025 10-K lists U.S. patent expiry for Mounjaro and Zepbound in 2036 and major European expiry in 2037. That gives the current franchise a long runway by pharma standards.
The second layer is pipeline depth in the same therapeutic area. Orforglipron adds an oral GLP-1 option. Retatrutide adds a next-generation triple agonist. Eloralintide adds a selective amylin receptor agonist with Phase III programs in obesity, osteoarthritis pain, obstructive sleep apnea, and add-on therapy. This is what a real moat looks like in pharma: not one blockbuster, but a conveyor belt of related blockbusters.
The third layer is business development. In 2026, Lilly announced acquisitions or agreements involving Orna Therapeutics, Syntessa Pharmaceuticals, Colonia Therapeutics, Ajax Therapeutics, and Ventix Biosciences, plus a licensing agreement with CSL for clazakizumab. That does not guarantee value creation, but it shows management is using the cash machine to widen the pipeline rather than simply admiring it.
Finally, Lilly’s commercial and manufacturing scale is part of the moat. The company sells in about 90 countries, has direct-to-consumer and self-pay access channels, and is already leveraging broad pharmacy and telehealth distribution for Koundeo. In obesity and diabetes, commercial muscle matters almost as much as molecule quality.
Operations have become strategically important because obesity demand can outrun supply. Lilly has been investing heavily in manufacturing, and that shows up in capital spending. Annual capex was $7.39B in 2023, $8.40B in 2024, and $7.84B in 2025. Those are large numbers even for a company of this size, and they reflect a deliberate buildout rather than maintenance spending.
Management framed manufacturing scale as a competitive advantage for Koundeo, explicitly calling out scalability. That is a meaningful point in a market where supply constraints have shaped market share. In the Q1 2026 call, David Ricks also said the economics of the obesity category are driven heavily by fixed costs, with latitude on pricing because volume expansion can be nonlinear when out-of-pocket costs come down.
That comment cuts both ways. It shows Lilly understands how to stimulate demand, but it also confirms that pricing pressure is real. The company said U.S. price declined 7% in Q1 2026, or 10% excluding a one-time rebate and discount adjustment. Europe grew 37% in constant currency, Japan 42%, China accelerated after Mounjaro entered the reimbursement drug list, and rest of world more than doubled in constant currency. The operating machine is clearly working, but it is working in a market where price and access are active variables, not fixed gifts from heaven.
Lilly operates inside a large and growing pharmaceutical market, but the real opportunity is narrower and more attractive than the broad industry average. Third-party market research estimates the global pharmaceutical market at roughly $1.78T in 2025 and $1.89T in 2026. More important for Lilly, Goldman Sachs has estimated the anti-obesity drug market could reach $100B by 2030, while Reuters-cited estimates place the broader global obesity drug market at $150B by the next decade.
The category is expanding quickly in real time. Lilly said the U.S. incretin analog obesity market grew more than 80% in Q1 2026, while the U.S. type 2 diabetes incretin analog market grew 11%. International incretin analog market sales increased 77% from the prior year period, according to management’s IQVIA-based commentary. Those are not normal pharma growth rates. They are land-grab numbers.
Lilly is well positioned because it already has leadership in both obesity and diabetes incretins, and it is extending into oral therapy. Industry data also points to oral GLP-1s as a major battleground, which aligns directly with Koundeo. If obesity treatment keeps broadening from specialty care into primary care and self-pay channels, Lilly’s addressable market expands materially.
Outside cardiometabolic disease, the market backdrop is more conventional. Oncology remains attractive but crowded. Immunology offers durable demand but payer scrutiny. Neuroscience has major unmet need, though commercialization is often slower and more uneven. Lilly’s advantage is that it does not need every market to be spectacular. It mostly needs obesity and diabetes to keep compounding while the rest of the portfolio adds incremental value.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Lilly’s end customers are patients, but the economic customers are more layered: physicians, employers, pharmacy benefit managers, government payers, and health systems. That matters because access drives volume. The company noted that self-pay represented about 45% of total Zepbound prescriptions in Q1 2026 and 55% of new prescriptions. In plain English, demand is strong enough that many patients are paying out of pocket.
The customer base in obesity is broadening. Lilly launched Employer Connect as a platform for employers to offer obesity medicines, and management said early employer interest was encouraging. CMS also extended the Medicare GLP-1 bridge program, set to begin no later than July 1, 2026 and run through December 2027, capping out-of-pocket costs at $50 per month for eligible patients. Those are concrete access channels, not abstract hopes.
In other therapeutic areas, the customer profile is more specialist-driven. Oncologists drive uptake for Verzenio, Jaypirca, and Inluriyo. Dermatologists and gastroenterologists matter for Ebglyss and Omvoh. Neurologists and memory-care networks matter for Kisunla. Lilly’s broad commercial footprint is useful because it can support both mass-market chronic therapy and specialist launches under one roof.
The main direct competitor in obesity and diabetes is Novo Nordisk. The rivalry is essentially tirzepatide versus semaglutide, with Lilly competing through Mounjaro and Zepbound against Ozempic and Wegovy. Lilly’s current edge is visible in market share and growth: Zepbound was the U.S. branded anti-obesity share leader in Q4 2025, and Mounjaro was the U.S. type 2 diabetes incretin share leader by the end of that quarter.
The next wave of competition is coming from Amgen, Pfizer, Roche, and AstraZeneca, all of which are advancing obesity assets. That said, Lilly is not defending one product against one rival. It is defending a platform. Tirzepatide is already commercial. Orforglipron is now approved in obesity. Retatrutide is posting positive Phase III data. That sequence gives Lilly more shots on goal than most peers.
In oncology, Lilly competes against Merck, Roche, Bristol Myers Squibb, AstraZeneca, Pfizer, Novartis, and others. Here the company is smaller than the biggest oncology franchises, but it has credible growth assets. Jaypirca’s 79% Q1 2026 sales growth and positive Phase III CLL data support that view. In immunology and neuroscience, Lilly is building rather than dominating, but the portfolio is broad enough to matter.
The 2025 10-K is blunt that competition is intense and global. That is standard pharma language, but in Lilly’s case it is especially relevant because obesity is attracting capital like a gold rush. The difference is that Lilly already owns productive acreage.
Macro risk for Lilly is less about GDP sensitivity and more about pricing, reimbursement, and regulation. In the U.S., CMS’s Medicare Drug Price Negotiation Program is active, and negotiated prices for the first 10 drugs were set for 2026 applicability. Lilly also faces the broader reality that obesity-drug coverage often requires employer opt-in and that many international payers still restrict reimbursement for weight-loss medicines.
Internationally, market access can require price concessions. Management said China revenue growth accelerated after Mounjaro entered the national reimbursement drug list for type 2 diabetes, and David Ricks noted that volume can far outstrip price concessions in markets where access broadens. That is encouraging, but it also means international growth can come with lower realized pricing.
On the positive side, regulators have also been active against compounded and unapproved GLP-1 products, which supports scaled branded manufacturers. Industry context points to FDA actions excluding semaglutide, tirzepatide, and liraglutide from certain bulk compounding pathways. That favors companies like Lilly with compliant manufacturing and established supply chains.
Geopolitical exposure exists through global supply chains and international sales, but Lilly’s business is not especially cyclical. The bigger external variable is public policy around drug pricing and obesity coverage. That is the sort of risk that does not show up in a spreadsheet until it suddenly does.
Cash and marketable securities totaled $5.8B at year-end 2025 against $28.8B of total debt, with net debt still manageable for a company generating rapid operating growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue surged from $34.1B in 2023 to $65.2B in 2025, and Q1 2026 sales jumped 56% year over year to $19.8B on tirzepatide strength.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $82B-$85B and non-GAAP EPS guidance to $35.50-$37.00, signaling another year of outsized growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 43.1x trailing earnings, 32.8x forward earnings, and 15.24x EV/revenue, Lilly trades at a premium that leaves less room for disappointment.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework spans $860 to $1,460, with $1,140 marking the fair value that separates a Buy from a more aggressive upside case.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Eli Lilly(LLY) is one of the rare mega-cap companies still posting growth rates that look more like an earlier-stage disruptor. Revenue, earnings, and margins are all moving in the right direction. The tirzepatide franchise is dominant, Koundeo adds a major oral growth vector, and the pipeline behind both remains unusually deep.
The investment debate is not about whether Lilly is a high-quality company. The numbers settled that argument a while ago. The real debate is how much of that quality is already in the stock. With a fair value estimate of $1,140, the answer is: a lot, but not all. That supports a Buy rating for investors who can tolerate premium valuation in exchange for premium execution.
In short, Lilly still looks like a market leader with a long runway. Just do not confuse a great company with an automatic bargain. Even the best engine can be overpriced if the market bolts too much chrome onto the hood.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Eli Lilly and Company (LLY) rises after a positive EU regulatory opinion for Jaypirca in chronic lymphocytic leukemia and fresh analyst support. The move pushed shares to a new high, reinforcing investor confidence in Lilly’s obesity-drug leadership and broader pipeline growth.
Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.